ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neff...
Q1 2026
May 13, 2026
FY 2025
Mar 9, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 13, 2025